Showing results (301-310 of 452) with videos related to

Sort By:
Pageof 46
Brain Sciences|April 30, 2021
A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple SclerosisAntonio Reia, Martina Petruzzo, Fabrizia Falco, et al.
Frontiers in Immunology|November 16, 2020
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple SclerosisTatiana Koudriavtseva, Annunziata Stefanile, Marco Fiorelli, et al.
Multiple Sclerosis and Related Disorders|July 27, 2024
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter studyFabrizia Falco, Federica Lamagna, Antonio Esposito, et al.
Multiple Sclerosis and Related Disorders|October 14, 2023
Low serum 25‑hydroxy-vitamin D levels are associated with cognitive impairment in multiple sclerosisAntonio Luca Spiezia, Fabrizia Falco, Andrea Manganelli, et al.
Molecular Psychiatry|June 7, 2025
Investigation of brain white matter and social cognition in schizophrenia and schizotypal personality disorder using neurite orientation dispersion and density imagingPhilip R Szeszko, Mary Kowalchyk, King-Wai Chu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 25, 2022
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)Marcello Moccia, Giuseppina Affinito, Bruno Ronga, et al.
Journal of Clinical Psychology in Medical Settings|January 22, 2022
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and ResilienceLaura Rosa, Cristiano Scandurra, Alessandro Chiodi, et al.
Multiple Sclerosis and Related Disorders|September 28, 2021
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trialMaria Petracca, Mario Quarantelli, Marcello Moccia, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 11, 2022
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With OcrelizumabDoriana Landi, Alfonso Grimaldi, Francesca Bovis, et al.
Pageof 46